Academic Journal
Description of the EuroTARGET cohort: A European collaborative project on TArgeted therapy in renal cell cancer-GEnetic- and tumor-related biomarkers for response and toxicity.
| Τίτλος: | Description of the EuroTARGET cohort: A European collaborative project on TArgeted therapy in renal cell cancer-GEnetic- and tumor-related biomarkers for response and toxicity. |
|---|---|
| Συγγραφείς: | van der Zanden LFM; Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands., Vermeulen SH; Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands., Oskarsdottir A; deCODE Genetics/Amgen, Reykjavik, Iceland., Maurits JSF; Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands., Diekstra MHM; Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center, Leiden, The Netherlands., Ambert V; University of Medicine and Pharmacy Carol Davila, Bucaresti, Romania, Bucuresti, Romania., Cambon-Thomsen A; Epidemiology and analyses in public health, Joint Unit 1027, Institut National de la Santé et de la Recherche Médicale (INSERM), Université Toulouse III Paul Sabatier, Faculty of Medicine, Toulouse, France., Castellano D; Medical Oncology Department, Hospital Universitario 12 de Octubre, I+12 Research Institute, (CiberOnc), Madrid, Spain., Fritsch A; Institute of Pharmacy, Clinical Pharmacy, University of Bonn, Bonn, Germany., Garcia Donas J; Medical Oncology, HM Hospitales-Centro Integral Oncológico HM Clara Campal, Madrid, Spain., Guarch Troyas R; Anatomía Patológica, Complejo Hospitalario de Navarra, Pamplona, Spain., Guchelaar HJ; Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center, Leiden, The Netherlands., Hartmann A; Department of Pathology, University Erlangen-Nürnberg, Erlangen, Germany., Hulsbergen-van de Kaa C; Department of Pathology, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands., Jaehde U; Institute of Pharmacy, Clinical Pharmacy, University of Bonn, Bonn, Germany., Junker K; Clinic of Urology and Paediatric Urology, Saarland University, Homburg, Germany., Martinez-Cardus A; Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, Barcelona, Catalonia, Spain., Masson G; deCODE Genetics/Amgen, Reykjavik, Iceland., Oosterwijk-Wakka J; Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands., Radu MT; University of Medicine and Pharmacy Carol Davila, Bucaresti, Romania, Bucuresti, Romania., Rafnar T; deCODE Genetics/Amgen, Reykjavik, Iceland., Rodriguez-Antona C; Hereditary Endorine Cancer Group, Spanish National Cancer Research Centre (CNIO) and Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain., Roessler M; CESAR central office, CESAR Central European Society for Anticancer Drug Research-EWIV, Vienna, Austria., Ruijtenbeek R; PamGene International B.V., 's-Hertogenbosch, The Netherlands., Stefansson K; deCODE Genetics/Amgen, Reykjavik, Iceland; Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavík, Iceland., Warren A; Department of Histopathology, Cambridge University Hospitals NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge, UK., Wessels L; Department of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Eisen T; Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge, UK., Kiemeney LALM; Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands. Electronic address: Bart.Kiemeney@radboudumc.nl., Oosterwijk E; Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands. |
| Πηγή: | Urologic oncology [Urol Oncol] 2017 Aug; Vol. 35 (8), pp. 529.e9-529.e16. Date of Electronic Publication: 2017 Apr 03. |
| Τύπος έκδοσης: | Journal Article; Multicenter Study; Observational Study |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Elsevier Country of Publication: United States NLM ID: 9805460 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2496 (Electronic) Linking ISSN: 10781439 NLM ISO Abbreviation: Urol Oncol Subsets: MEDLINE |
| Imprint Name(s): | Publication: 2003- : Philadelphia, PA : Elsevier Original Publication: New York, NY : Elsevier Science |
| Ιατρικοί όροι (MeSH): | Biomarkers, Tumor/*analysis , Carcinoma, Renal Cell/*drug therapy , Kidney Neoplasms/*drug therapy , Molecular Targeted Therapy/*methods, Antineoplastic Agents/therapeutic use ; Carcinoma, Renal Cell/genetics ; Indoles/therapeutic use ; Kidney Neoplasms/genetics ; Niacinamide/analogs & derivatives ; Niacinamide/therapeutic use ; Phenylurea Compounds/therapeutic use ; Protein Kinase Inhibitors/therapeutic use ; Pyrimidines/therapeutic use ; Pyrroles/therapeutic use ; Sulfonamides/therapeutic use ; Adult ; Aged ; Aged, 80 and over ; Cohort Studies ; Female ; Humans ; Indazoles ; Male ; Middle Aged ; Prospective Studies ; Sorafenib ; Sunitinib ; Young Adult |
| Περίληψη: | Objective: For patients with metastatic renal cell cancer (mRCC), treatment choice is mainly based on clinical parameters. With many treatments available and the limited response to treatment and associated toxicities, there is much interest in identifying better biomarkers for personalized treatment. EuroTARGET aims to identify and characterize host- and tumor-related biomarkers for prediction of response to tyrosine kinase inhibitor therapy in mRCC. Here, we describe the EuroTARGET mRCC patient cohort. Methods and Materials: EuroTARGET is a European collaborative project designed as an observational study for which patients with mRCC were recruited prospectively in 62 centers. In addition, 462 patients with mRCC from previous studies were included. Detailed clinical information (baseline and follow-up) from all patients was entered in web-based case record forms. Blood was collected for germline DNA and pharmacokinetic/pharmacodynamic analyses and, where available, fresh-frozen tumor material was collected to perform tumor DNA, RNA, kinome, and methylome analyses. Results: In total, 1,210 patients with mRCC were included. Of these, 920 received a tyrosine kinase inhibitor as first-line targeted treatment (sunitinib [N = 713, 78%], sorafenib [N = 41, 4%], or pazopanib [N = 166, 18%]) and had at least 6 months of outcome assessment (median follow-up 15.3 months [interquartile range: 8.5-30.2 months]). Germline DNA samples were available from 824 of these patients, fresh-frozen tumor material from 142 patients, fresh-frozen normal kidney tissue from 95 patients, and tissue microarrays created from formalin-fixed paraffin-embedded tumor material from 247 patients. Of the 920 patients, germline DNA variant chip data were successfully generated for 811 patients (Illumina HumanOmniExpress BeadChip). For 80 patients, next-generation exome sequencing of germline and tumor DNA was performed, tumor RNA sequencing was performed for 124 patients, kinome activity measured and processed for 121 patients (PamChip), and methylome data (Illumina Infinium HumanMethylation450 BeadChip) were created for 116 RCC tissues (and 23 normal kidney tissues). For 73 out of the 920 patients, all platform data types were generated. In addition, 40 patients were included in a pharmacokinetic/pharmacodynamic phase IV substudy. Conclusions: Analysis of EuroTARGET cohort data will contribute to personalization of therapy for patients with mRCC. The extensive clinical data and multiplatform EuroTARGET data will be freely available. (Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.) |
| Contributed Indexing: | Keywords: Biomarker; Genomics; Metastatic renal cell carcinoma; Therapy response; Transcriptomics; Tyrosine kinase inhibitor |
| Substance Nomenclature: | 0 (Antineoplastic Agents) 0 (Biomarkers, Tumor) 0 (Indazoles) 0 (Indoles) 0 (Phenylurea Compounds) 0 (Protein Kinase Inhibitors) 0 (Pyrimidines) 0 (Pyrroles) 0 (Sulfonamides) 25X51I8RD4 (Niacinamide) 7RN5DR86CK (pazopanib) 9ZOQ3TZI87 (Sorafenib) V99T50803M (Sunitinib) |
| Entry Date(s): | Date Created: 20170408 Date Completed: 20180509 Latest Revision: 20211204 |
| Update Code: | 20260130 |
| DOI: | 10.1016/j.urolonc.2017.03.009 |
| PMID: | 28385611 |
| Βάση Δεδομένων: | MEDLINE |
| ISSN: | 1873-2496 |
|---|---|
| DOI: | 10.1016/j.urolonc.2017.03.009 |